News Release

First-of-its-kind procedure combines scalp, skull, kidney and pancreas transplant

Peer-Reviewed Publication

Wolters Kluwer Health

May 27, 2016 - Simultaneous transplantation of a "composite" skull and scalp flap plus a kidney and pancreas--all from the same donor--provided excellent outcomes for a patient with a non-healing scalp defect and declining organ kidney and pancreas function, according to a report in the June issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).

The experience may open the way to further procedures combining "vascularized composite allotransplantation" (VCA) with organ transplants, in patients who have already accepted the need for lifelong immunosuppressive therapy. "Hopefully, this case and others like it will help to widen the narrow indications for this fascinating new field of reconstructive surgery," write Dr. Jesse Creed Selber of The University of Texas M.D. Anderson Cancer Center and colleagues.

Combined Transplants Are New Option for Organ Recipients Who Already Need Immunosuppression

Vascularized composite allotransplantation refers to transplant procedures combining different types of tissues, such as skin, muscle, blood vessels, nerves, and bone. Face transplantation is the best-known type of VCA; hand transplantation is another example.

Other types of VCA flaps offer a potentially new approach to reconstruction for patients with major skull and facial defects. But they also have a major drawback--the need for immunosuppressive drugs to prevent the recipient's immune system from rejecting the transplant. Patients who also need or have already undergone organ transplantation have already accepted the risks of lifelong immunosuppressive therapy.

Dr. Selber and colleagues outline their experience with combined VCA and organ transplantation in a 55-year-old man. Two decades earlier, he had undergone kidney transplantation for diabetic kidney disease, but that kidney was now failing. He also had a large, unstable wound of the scalp and skull--a complication of surgery and radiation therapy for a scalp tumor. (An increased risk of cancers is one of the risks of long-term immunosuppressive treatment.)

Because the patient was already receiving immunosuppressive therapy and would need another organ transplant in any case, doctors suggested a procedure in which a VCA of scalp and skull would be performed at the same time as a kidney/pancreas transplant, with all transplants coming from the same donor. After weighing his alternatives and discussing the risks and benefits with the surgical team, the patient opted for this combined procedure.

After 18 months on the waiting list, a suitable deceased donor became available--providing not only basic immunologic compatibility but also a match in terms of skin color and quality, hair pattern, and head size. The combined VCA and double-organ transplant procedure required 20 physicians and 15 hours in the operating room.

At the end of the procedure, both transplants were receiving good blood supply and the transplanted organs were functioning normally. An episode of rejection of the scalp/skull transplant occurred after a few months, but was successfully treated. One year after the procedure, the patient was doing well, including good cosmetic appearance of the transplanted scalp.

In this case, the patient's pre-existing organ transplant and immunosuppressive therapy opened the way for VCA to reconstruct a serious scalp/skull defect. The fact that both the composite transplant and organs are from the same donor minimizes the risk of rejecting tissues stimulated by a second donor's tissue.

As the experience with VCA continues to evolve, combining composite reconstruction of complex skull and facial deformities plus organ transplantation presents a unique opportunity to solve difficult clinical problems while avoiding some of the complex ethical choices involved with VCA. Dr. Selber adds, "Our experience is a first step toward widening the narrow indications for VCA to patients with pre-existing immunosuppression."


Click here to read "Simultaneous Scalp, Skull, Kidney, and Pancreas Transplant from a Single Donor."

Article: "Simultaneous Scalp, Skull, Kidney, and Pancreas Transplant from a Single Donor" (doi: 10.1097/PRS.0000000000002153)

Plastic and Reconstructive Surgery® is published by Wolters Kluwer.

About Plastic and Reconstructive Surgery

For 70 years, Plastic and Reconstructive Surgery® ( has been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon. The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery® brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues.

About ASPS

The American Society of Plastic Surgeons (ASPS) is the world's largest organization of board-certified plastic surgeons. Representing more than 7,000 Member Surgeons, the Society is recognized as a leading authority and information source on aesthetic and reconstructive plastic surgery. ASPS comprises more than 94 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada. ASPS advances quality care to plastic surgery patients by encouraging high standards of training, ethics, physician practice and research in plastic surgery. You can learn more and visit the American Society of Plastic Surgeons at or and

About Wolters Kluwer

Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The group serves customers in over 180 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

For more information about our products and organization, visit, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.